Royalty Report: cell therapy, Medical, Drugs – Collection: 330906


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 6


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6

Primary Industries

  • cell therapy
  • Medical
  • Drugs
  • Stem cells
  • Drug Discovery
  • Supply
  • Therapeutic
  • bone marrow

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 330906

License Grant
University hereby grants to Licensee and Licensee hereby accepts an exclusive license, subject to any rights of the government in the Territory for the Field of Use, with the right to sublicense, under the Technology Rights and an exclusive license to the technology developed as of the Effective Date by Joshua M. Hare, M.D., that is not encumbered by any third party rights, which in University’s sole discretion, Is necessary to practice the Technology Rights to research, develop, make, have made, use, sell and import the Product(s) and to practice the Process(es) described and/or claimed In the Technology Rights,
License Property
Technology Rights shall mean Cell Aging Frailty-related MSC technology specifically set forth in Agreement.
Field of Use
Field of Use shall mean all fields for aging-related frailty.
Aging Frailty is a common geriatric condition that disproportionately increases a patient’s risk for poor clinical outcomes due to disease and injury, and is widely believed by geriatricians to ultimately be treatable.  MSCs are biological entities obtained from living humans that can pose risks to the recipient.  MSC therapies require many manufacturing steps. Cells must be harvested from donor tissue, isolated, and expanded in cell culture to produce a sufficient number of cells for use. Each step carries risks for contamination by other cells, microbes, or adventitious agents. The transfer of cells into a recipient can also carry risks and complications associated with the procedure itself, and a recipient may reject the transplanted cells.

IPSCIO Record ID: 346226

License Grant
University granted us an exclusive, worldwide license under such patents and a nonexclusive royalty-bearing, worldwide license for such know-how to research, develop, commercialize and manufacture FCR001 and products containing FCR001 in all fields, without limitation. University also granted us the right to grant sublicenses in accordance with the University License Agreement.
License Property
The rights granted relate to certain licensed patent rights and know-how related to human facilitating cells for the Facilitated Allo-HSCT Therapy.

Aallogeneic hematopoietic stem cell transplantation (allo-HSCT), called Facilitated Allo-HSCT Therapy.  

The product candidate, FCR001, which is central to Facilitated Allo-HSCT Therapy, is a novel allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor, who is also the organ donor in the case of organ transplantation. FCR001 is rapidly processed in the GMP facility using proprietary manufacturing methods. Then, at the time of the transplant, FCR001 is administered to the recipient following nonmyeloablative conditioning, which is designed to be less toxic than myeloablative conditioning. A fully myeloablative conditioning regimen consists of a combination of agents and high doses of total body irradiation that destroy hematopoietic stem cells (HSCs) in the bone marrow and results in profound depletion of HSC-derived cells within one to three weeks following administration that is irreversible, and in most instances is fatal unless rescued by a stem cell transplant. The nonmyeloablative conditioning for FCR001 entails lower doses of chemotherapy and total body irradiation, causes less depletion of blood cells and does not require stem cell support for the recipient to resume the production of blood cells and platelets.

Allo-HSCT Therapy has the potential to treat a range of severe autoimmune diseases and severe non-malignant blood, immune and metabolic disorders, in each case with potential for similar outcomes to what has previously been observed with HSCT, while mitigating the toxicities, morbidities and extended hospital stay associated with the conditioning regimen typically required by HSCT.

Field of Use
Field of use is for to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders, in all fields, without limitation.

Facilitated Allo-HSCT Therapy could prevent organ rejection without the morbidity and mortality that has been associated with the use of lifelong anti-rejection medicines, also known as chronic immunosuppression.

IPSCIO Record ID: 372470

License Grant
The University grants a license under the Biological Material in the Licensed Field of Use to make, have made, use, have used, import, have imported, offer to sell, have offered to sell, sell and have sold Licensed Product in the Licensed Territory.  The license is nonexclusive in the Licensed Field of Use.
License Property
The University has rights to biological material known as 293T Cell Line.

The HEK293T cells are maintained in disposable flasks until sufficient cell mass has been generated to fill approximately 40 ten tray cell factories, or TTCFs, then transferred and allowed to adhere to the bottom of the trays.  Adherent cells are transfected with multiple plasmids encoding all the genetic material required to assemble the lentiviral vector carrying the functional gene of interest.  The transfected HEK293T cells then assemble our lentiviral vectors packaged with the functional gene of interest, which bud off into the cell culture media. The media containing the assembled vectors is harvested, purified, concentrated and formulated prior to freezing for storage. These finished lentiviral vectors are what is ultimately used to transduce the targeted cells isolated from the patient.

Field of Use
Licensed Field of Use means any commercial and/or non-commercial use of Biological Material for
• research, and non-clinical and clinical development purposes; and
• human and animal gene therapy products.

IPSCIO Record ID: 329677

License Grant
University hereby grants to the Licensee and Licensee hereby accepts from University, upon the terms and conditions herein specified, an exclusive, worldwide license to use Subject Technology during the term of this Agreement.  Licensee shall have the right to sublicense its rights hereunder without the consent of University.
License Property
Invention shall mean the Yeast based G-Protein Coupled Receptor Screening Technology, as invented by Robert Lefkowitz, Marc Caron, Henrik G. Dohlman and Klim King and described in King et al, 'Control of Yeast Mating Signal Transduction by a Mammalian beta-2 Adrenergic Receptor and Gs alpha subunit, Science, pp121-123, October 5, 1990, and in PCT patent application WO 92/05244, published 2 April 1992.
Field of Use
Field of use is for any human medical therapeutic compound covering hybrid yeast cell technologies in the medical industry.  The hybrid yeast cell technology is a compound profiling technique is used as a bait to screen protein libraries prepared from any tissue, cell type or organism.

The Licensee believes that hybrid yeast cells are highly effective for screening compounds. Hybrid yeast cells can be used to measure the biological activity of the human signaling pathway in which intervention is desired. In addition, hybrid yeast cells contain a single human receptor which connects to a defined signaling pathway.

IPSCIO Record ID: 213098

License Grant
The Israeli Licensee signed an agreement with the Israeli Licensor to conduct a Phase I/II trial of PLX-PAD cell therapy for the treatment of Steroid-Refractory Chronic Graft-Versus-Host-Disease ('GvHD').
License Property
PLX-PAD – PLacental eXpanded cells are placenta-derived cells that are designed to be administered to patients without the need for tissue or genetic matching.
Field of Use
The Licensee is a developer of placenta-based cell therapy products.

Graft-versus-host disease (GvHD) is a medical complication following the receipt of transplanted tissue from a genetically different person. GvHD is commonly associated with stem cell transplant (bone marrow transplant), but the term also applies to other forms of tissue graft. Immune cells (white blood cells) in the donated tissue (the graft) recognize the recipient (the host) as foreign (nonself).

IPSCIO Record ID: 330905

License Grant
Licensor, an affiliate of Licensee Chief Science Officer,  hereby grants to Licensee an exclusive license, subject to any rights of the government in the Territory for the Field of Use, with the right to sublicense, under the Patent Rights and Technology to research, develop, make, have made, use, sell and import the Product(s) and to practice the Process claimed in the Patent Rights.
License Property
U.S. Patent Application #13/819,154 – Bone Marrow Derived CD271 Precursor Cells For Cardiac Repair

Technology known as
Bone Marrow Derived CD271 Precursor Cells For Cardiac Repair
Bone Marrow Derived CD271 Precursor Cells For Cardiac Repair

Field of Use
CD271+ technology is a subpopulation of bone marrow-derived MSCs.

Field of Use shall mean any aging related diseases or indications including frailty, metabolic syndrome, loss of muscle due to aging or frailty, and neurocognitive disorders.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.